Silent artery plaques may appear in one in 13 adults before age 30

A large international study known as the REACT study has mapped the prevalence of silent atherosclerosis across the adult lifespan. The findings indicate that silent artery plaques may appear in as many as one in 13 adults before they reach the age of 30. Furthermore, reports from Demócrata suggest that more than half of healthy young adults exhibit signs of this silent atherosclerosis. These developments were highlighted during the ESC 2026 congress, emphasizing that this burden of arterial plaque is far more widespread than previously understood in younger populations. Coverage from Medical Xpress, EMJ, and HCPLive emphasizes that this condition is frequently missed by standard risk tools currently used by clinicians. The EMJ reports that imaging techniques were essential in revealing the true burden of these silent plaques.

Meanwhile, Medical Device Network focuses on the systemic implications, suggesting that the ability to identify silent atherosclerosis could play a critical role in reducing the overall global cardiovascular disease (CVD) burden. The consensus across these outlets is that traditional screening methods are insufficient for detecting early-stage arterial buildup. The context for this trend is the recognition of a gap in early detection. Atherosclerosis is typically viewed as a condition that develops later in life, but the REACT study provides a new map showing its presence much earlier. By establishing that healthy young adults may already be carrying silent plaques, the research suggests that the window for intervention needs to shift. This shift is necessary because these plaques do not present obvious symptoms, meaning they remain hidden until a more serious cardiovascular event occurs, which is why the imaging data from the ESC 2026 event is significant.

Future attention will likely focus on the integration of the REACT study's findings into clinical practice. Because HCPLive specifically noted that standard risk tools are missing these cases, the medical community may look toward updated diagnostic protocols. The primary objective moving forward, as outlined by Medical Device Network, is the reduction of the global CVD burden through better identification. Observers will be monitoring whether new imaging standards are adopted to replace or supplement the current risk tools that have failed to capture the prevalence of silent atherosclerosis in adults under 30.